Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WGI-0301 in Advanced Solid Tumors
NCT05267899Phase 1Recruiting
- Sponsor
- Haichang Biotech
- Start
- Aug 2022
- Primary completion
- Oct 2024
- Modality
- Modified DNA Oligonucleotides, Lipid-based Nanoparticles, Single-strand DNA
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of WGI-0301 in solid tumor, sponsored by Haichang Biotech. Primary endpoints: Safety and tolerability at 16 months and Recommended Phase 2 Dose at 16 months. Started Aug 2022; status: recruiting.
02
Drugs
WGI-0301
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05267899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05267899.